Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents is a research paper published in Translational Cancer Research (2020). On theSindex it has a DataRank of 0.425. It has been cited 16 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.425
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NCI NIH HHS
Grant: R44 CA213462
NIMHD NIH HHS
Grant: U54 MD007595
NIMHD NIH HHS
Grant: G12 MD007595
National Institutes of Health
Grant: 3U54MD007595-14S1
Xavier RCMI Renewal Application-Overall
FWCI
0.81
Citation Percentile
0.7%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals